<International Circulation>:Could please highlight what you think were the main highlights of this year’s ESC congress?

    Professor Fausto Pinto:We have had a large number of trials which have been submitted at this year’s congress and we are very happy to be the platform for their communication. I would like to select a few of these， in particular the SHIFT Study which explored the new potential benefits of ivabradine which reduces heart rate.  This specific trial was done in a large number of patients over 6500 with heart failure and it demonstrated a reduction in cardiac death from heart failure as well as a reduction of hospitalized sessions attributed to heart failure. The results of the study have to be digested now after its presentation and it certainly represents a new added value in the treatment of heart failure which is something we have been waiting for quite some time.  I would also like to highlight some other trials based on their use of new anti-coagulant and anti platelet agents either in the setting of acute coronary syndrome or PCI including the AVERROES Trial. This was a trial which compared apixaban in patients with atrial fibrillation and it showed patients who were administrated with this drug compared with the group on aspirin showed decreased rates of strokes with the same degree of haemorrhage.  The study showed that this could be another drug which may be used by cardiologists to treat patients with atrial fibrillation particularly those who are not tolerant to antagonists of vitamin K such as warfarin which as we know has numerous problems.  These are just two of the many trials which were presented at ESC 2010 that I would like to highlight in terms of their relevance to clinical application.  

   《国际循环》：您认为本届ESC年会的热点是什么？
    Pinto教授：本届ESC年会收到了研究者递交的多个临床试验的结果，我们很高兴能够为大家提供一个交流的平台。我想特别指出其中几项试验，尤其是SHIFT研究。该研究观察了伊伐布雷定降低心率的潜在益处，这是一个新发现。SHIFT研究样本量大，入选了6，500例以上心衰患者，提示伊伐布雷定能够减少心衰患者的心血管死亡和因心衰入院。在SHIFT研究结果公布之后，我们还需要进一步消化其研究结果。毫无疑问，这一研究结果提示伊伐布雷定治疗心衰还能带来额外益处，这是新的发现，是我们一直以来所期待的。我还想特别指出一些试验，这些试验观察了新型抗凝药物和抗血小板药物用于急性冠脉综合征或PCI。例如AVERROES试验观察了阿哌沙班用于房颤患者，显示阿哌沙班较阿司匹林能够减少卒中发生，同时两种治疗的出血发生率相近。该研究显示，心内科医生可应用阿哌沙班来治疗房颤，尤其是不能耐受华法林等维生素K拮抗剂的患者，我们知道这一类药物有很多问题。这只是在本届ESC年会上公布的众多试验中公布的两项试验，由于它们与临床实践密切相关，所以我想重点指出这两项试验。